Chenguang Biotech Group (300138) - Total Assets
Based on the latest financial reports, Chenguang Biotech Group (300138) holds total assets worth CN¥7.96 Billion CNY (≈ $1.16 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300138 total equity for net asset value and shareholders' equity analysis.
Chenguang Biotech Group - Total Assets Trend (2007–2024)
This chart illustrates how Chenguang Biotech Group's total assets have evolved over time, based on quarterly financial data.
Chenguang Biotech Group - Asset Composition Analysis
Current Asset Composition (December 2024)
Chenguang Biotech Group's total assets of CN¥7.96 Billion consist of 75.5% current assets and 24.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.0% |
| Accounts Receivable | CN¥467.93 Million | 5.2% |
| Inventory | CN¥3.86 Billion | 42.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥345.69 Million | 3.8% |
| Goodwill | CN¥593.86K | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Chenguang Biotech Group's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Chenguang Biotech Group (300138) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chenguang Biotech Group's current assets represent 75.5% of total assets in 2024, an increase from 70.0% in 2007.
- Cash Position: Cash and equivalents constituted 20.0% of total assets in 2024, up from 1.9% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 5.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 42.8% of total assets.
Chenguang Biotech Group Competitors by Total Assets
Key competitors of Chenguang Biotech Group based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
New Hope Liuhe Co Ltd
SHE:000876
|
China | CN¥116.87 Billion |
|
Austevoll Seafood ASA
OL:AUSS
|
Norway | Nkr53.09 Billion |
|
SLC Agrícola S.A
SA:SLCE3
|
Brazil | R$21.34 Billion |
|
Sipef NV
BR:SIP
|
Belgium | €1.21 Billion |
|
Shandong Xiantan Co Ltd
SHE:002746
|
China | CN¥7.77 Billion |
|
Vital Farms Inc
NASDAQ:VITL
|
USA | $518.74 Million |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
China | CN¥3.95 Billion |
|
Inghams Group Ltd
AU:ING
|
Australia | AU$2.36 Billion |
Chenguang Biotech Group - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 1.78 | 2.04 |
| Quick Ratio | 0.94 | 1.23 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.61 Billion | CN¥2.45 Billion | CN¥1.49 Billion |
Chenguang Biotech Group - Advanced Valuation Insights
This section examines the relationship between Chenguang Biotech Group's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | CN¥9.02 Billion |
| Market Capitalization | $815.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chenguang Biotech Group's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chenguang Biotech Group's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chenguang Biotech Group (2007–2024)
The table below shows the annual total assets of Chenguang Biotech Group from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.02 Billion ≈ $1.32 Billion |
+5.66% |
| 2023-12-31 | CN¥8.54 Billion ≈ $1.25 Billion |
+23.34% |
| 2022-12-31 | CN¥6.92 Billion ≈ $1.01 Billion |
+16.26% |
| 2021-12-31 | CN¥5.96 Billion ≈ $871.43 Million |
+27.94% |
| 2020-12-31 | CN¥4.65 Billion ≈ $681.10 Million |
+3.27% |
| 2019-12-31 | CN¥4.51 Billion ≈ $659.53 Million |
+34.25% |
| 2018-12-31 | CN¥3.36 Billion ≈ $491.25 Million |
+16.86% |
| 2017-12-31 | CN¥2.87 Billion ≈ $420.38 Million |
+15.26% |
| 2016-12-31 | CN¥2.49 Billion ≈ $364.72 Million |
+25.17% |
| 2015-12-31 | CN¥1.99 Billion ≈ $291.39 Million |
+32.03% |
| 2014-12-31 | CN¥1.51 Billion ≈ $220.70 Million |
-7.57% |
| 2013-12-31 | CN¥1.63 Billion ≈ $238.76 Million |
+12.87% |
| 2012-12-31 | CN¥1.45 Billion ≈ $211.54 Million |
+29.55% |
| 2011-12-31 | CN¥1.12 Billion ≈ $163.29 Million |
-2.88% |
| 2010-12-31 | CN¥1.15 Billion ≈ $168.13 Million |
+185.21% |
| 2009-12-31 | CN¥402.85 Million ≈ $58.95 Million |
+4.57% |
| 2008-12-31 | CN¥385.24 Million ≈ $56.37 Million |
+105.80% |
| 2007-12-31 | CN¥187.20 Million ≈ $27.39 Million |
-- |
About Chenguang Biotech Group
ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oleo… Read more